
    
      To assess the long-term safety and tolerability of oral lubiprostone 12 or 24mcg capsules
      dosed twice daily (BID) when administered orally for 24 weeks in pediatric participants with
      functional constipation. Evaluation of lubiprostone safety and tolerability is the primary
      objective in this study.
    
  